Antisense modulation of survivin expression

Details for Australian Patent Application No. 2003205017 (hide)

Owner Isis Pharmaceuticals, Inc.

Inventors Bennett, C. Frank; Swayze, Eric E.; Ackermann, Elizabeth J.; Cowsert, Lex M.

Agent FB Rice

Pub. Number AU-B-2003205017

Parent 61598

Filing date 27 June 2003

Wipo publication date 24 July 2003

Acceptance publication date 15 December 2005

International Classifications

C07H 21/02 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C07C 21/04 (2006.01) Acyclic unsaturated compounds containing halogen atoms

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

10 July 2003 Complete Application Filed

24 July 2003 Application Open to Public Inspection

  Published as AU-B-2003205017

15 December 2005 Application Accepted

  Published as AU-B-2003205017

13 April 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003205018-Ingot Handling

2003205016-Hemostatic wound dressing containing aldehyde-modified polysaccharide